{"schema_version":"secwatch.filing_event.v1","accession":"0001055726-26-000024","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2026-08-12T20:07:49+00:00","discovered_at":"2026-08-12T20:09:07.487133+00:00","generated_at":"2026-08-12T20:09:27.368788+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"INOVIO reports Q2 2026 net loss of $6.0M; INO-3107 PDUFA on Oct 30, 2026","bullets":["Net loss of $6.0M ($0.07/share) vs $23.5M ($0.61) in Q2 2025; includes $13.9M non-cash warrant gain.","Cash and investments $36.7M at June 30, 2026, plus $18.3M from July offering; runway into late Q1 2027.","FDA review of INO-3107 BLA continues; PDUFA target action date October 30, 2026; commercial launch prep ongoing.","ApolloBio reported positive Phase 3 topline for VGX-3100 in China for cervical dysplasia.","Operating expenses fell to $18.6M from $23.1M YoY; R&D down to $10.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001055726-26-000024","json":"https://secwatch.observer/filing/0001055726-26-000024.json","markdown":"https://secwatch.observer/filing/0001055726-26-000024.md","text":"https://secwatch.observer/filing/0001055726-26-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/0001055726-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000105572626000024/ino-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:09:27.368788+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}